BioSpace News Archive

Aquestive Therapeutics, Inc. announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today provided an update on the progress of its platform of GeneTAC™ portfolio assets and reported fourth quarter and full year 2023 financial results.

Tyra Biosciences, Inc. (Nasdaq: TYRA) today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent corporate progress.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2023 financial results and business updates.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2023.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

AEON Biopharma, Inc. announced it has entered definitive agreements relating to a private placement of $15 million aggregate principal amount of senior secured convertible notes with Daewoong Pharmaceutical Co., LTD.

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.

Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd., announced that it is extending its joint validation trials for its biofungicides conducted by Bayer AG, a global leader in the agriculture industry, after successful first-year laboratory and greenhouse testing.